Bacteroidetes

Global Microbiome Sample Preparation Technology Market Analysis Report 2022: A $411 Million market by 2030 - Innovation in Genome Sequencing Techniques Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Health, Biotechnology, R, Enzyme, Workflow, Dysbiosis, Food, Degenerative disease, Inflammatory bowel disease, Machine learning, DNA, Diet, Research, Acquisition, Bias, Application, Inflammation, Disease, Proteobacteria, Therapy, Growth, Ecosystem, Microbiota, COVID-19, Crohn's disease, Metabolomics, Infection, Risk, IBD, Weizmann Institute of Science, Patient, Antibiotics, Fine chemical, Dietary supplement, Pharmaceutical industry, Bacteroidetes

The rising importance of the microbiome as an area of study for Inflammatory Bowel Disease (IBD) research along with the innovation in genome sequencing techniques are significant contributors to the market growth.

Key Points: 
  • The rising importance of the microbiome as an area of study for Inflammatory Bowel Disease (IBD) research along with the innovation in genome sequencing techniques are significant contributors to the market growth.
  • Other factors such as the rising penetration of personalized medicine are likely to impact the usage of microbiome sample preparation technology.
  • The COVID-19 pandemic accelerated the use of microbiome sample preparation technology for the research proposed.
  • Microbiome analysis allows clinicians to identify specific unknown pathogens and track the microbiota and microbiome in regards to illness status and treatment

Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer’s and Chronic Inflammation

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Consumer, Other Health, Pharmaceutical, Other Science, Mental health, Research, Managed care, General Health, Hospitals, Science, Dental, Seniors, Branches of biology, Medical specialties, Microbiology, Membrane biology, Bacterial vaginosis, Bacteroidetes, Porphyromonas gingivalis, Reproductive system, Sexual health, Biofilm, Virulence, Vesicle

View the full release here: https://www.businesswire.com/news/home/20210729006009/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210729006009/en/
    Using KB proprietary methods, KB has identified and eliminates a primary driver of our most deadly diseases, Porphyromonas gingivalis and all of its unique virulence factors.
  • A larger HagA Domain virulence factor is found in many AD and some aged matched control brain tissues.
  • Porphyromonas gingivalis Outer Membrane Vesicles as the major drivers of and source for the toxic insult and iron accumulation/deposition in Alzheimers Disease.
  • Porphyromonas gingivalis (Pg) is a primary oral pathogen in the widespread biofilm-induced chronic multi-systems inflammatory disease(s) including Alzheimers disease (AD).

Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

Retrieved on: 
Wednesday, July 21, 2021
Research, Seniors, Dental, Clinical trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Branches of biology, Microbiology, Medical specialties, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Gingipain, Periodontology, Biofilm

In a second presentation at IADR 2021, Cortexyme presented data from preclinical studies demonstrating that atuzaginstat was efficacious in reversing alveolar bone loss induced by oral P. gingivalis infection.

Key Points: 
  • In a second presentation at IADR 2021, Cortexyme presented data from preclinical studies demonstrating that atuzaginstat was efficacious in reversing alveolar bone loss induced by oral P. gingivalis infection.
  • We look forward to reporting top-line data from the REPAIR sub-study in the fourth quarter 2021.
  • ET, new data will be presented demonstrating the efficacy of atuzaginstat and COR588 to penetrate in vitro surface attached biofilms.
  • Atuzaginstat Efficacious in Mouse Model of Periodontal Disease: At Cortexymes IADR 2021 poster session titled Novel lysine-gingipain inhibitor atuzaginstat (COR388) is efficacious in a mouse model of periodontal disease (Abstract #1756) taking place Friday, July 23, 2021, starting at 11:00 a.m.

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Retrieved on: 
Tuesday, June 1, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Organ systems, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Periodontal disease, Periodontology, Immunoglobulin G

All subjects had evidence of P. gingivalis-specific IgG at baseline, with 78% exhibiting higher antibody titers associated with periodontal disease.

Key Points: 
  • All subjects had evidence of P. gingivalis-specific IgG at baseline, with 78% exhibiting higher antibody titers associated with periodontal disease.
  • (Kojima et al., 1997)
    More than 90% of participants in the REPAIR periodontal sub-study have moderate to severe periodontal disease at baseline.
  • 64% of the trial participants carry at least one ApoE4 gene and these participants are stratified across the three treatment groups.
  • Baseline biomarker data analyses presented at ASCP include 100% of the enrolled subjects with baseline CSF or serum samples available for analysis.

Cortexyme Provides Business Update and Reports First Quarter 2021 Results

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Organ systems, Gingipain, Periodontal disease, Forward-looking statement

Top-line data for the REPAIR sub-study, which evaluates atuzaginstat in treating periodontitis, is expected in the fourth quarter 2021.\nCOR588 IND-enabling studies are proceeding with a first-in-human study expected to begin in the third quarter 2021.

Key Points: 
  • Top-line data for the REPAIR sub-study, which evaluates atuzaginstat in treating periodontitis, is expected in the fourth quarter 2021.\nCOR588 IND-enabling studies are proceeding with a first-in-human study expected to begin in the third quarter 2021.
  • Arginine gingipain is a distinct target associated with P. gingivalis that contributes to bacterial survival, replication, and toxicity.
  • To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.\nStatements in this news release contain \xe2\x80\x9cforward-looking statements\xe2\x80\x9d that are subject to substantial risks and uncertainties.
  • Forward-looking statements contained in this news release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005239/en/\n'

Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation

Retrieved on: 
Monday, March 8, 2021
Mental health, Health, Infectious diseases, Dental, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Organ systems, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Gingipain, Parkinson's disease, Parkinson

In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis (P. gingivalis) in the development of Alzheimers disease at AD/PD 2021, the 15th International Conference on Alzheimers & Parkinsons Diseases, which is being held virtually March 9-14, 2021.

Key Points: 
  • In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis (P. gingivalis) in the development of Alzheimers disease at AD/PD 2021, the 15th International Conference on Alzheimers & Parkinsons Diseases, which is being held virtually March 9-14, 2021.
  • We are collectively eager to further understand the mechanism of gingipain inhibition and its potential to improve the lives of patients suffering from Parkinsons disease.
  • There is a tremendous unmet medical need for PD, and the potential link between P. gingivalis and PD demands further exploration.
  • We are pleased to partner with the PSG and look forward to advancing our work in Parkinsons disease as we make progress towards improving patient outcomes.

Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease Conference

Retrieved on: 
Thursday, November 5, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Clinical medicine, Medical specialties, Medicine, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Periodontology, Alzheimer's disease, Periodontal disease

The data (Abstract #OC19) are being presented today in an oral session at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD 2020), which is taking place as a digital event November 4-7.

Key Points: 
  • The data (Abstract #OC19) are being presented today in an oral session at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD 2020), which is taking place as a digital event November 4-7.
  • A variety of AD-associated biomarkers have been identified in the vast majority of patients enrolled in the trial to date.
  • Additionally, all patients enrolled in the trial and analyzed to date have evidence of immune response to systemic P. gingivalis infection.
  • More than 90 percent of patients in the trials dental sub-study had moderate to severe periodontal disease at baseline.

Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases

Retrieved on: 
Tuesday, July 28, 2020
Cardiology, Biotechnology, FDA, Health, Seniors, Pharmaceutical, Mental health, Infectious diseases, Consumer, Dental, Clinical trials, Medical specialties, Reproduction, Health, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Gingipain, Atherosclerosis, Myeloperoxidase, Forsyth Institute, Cortexyme, Inc.

Cortexyme also provided data demonstrating the therapeutic potential of its lead compound, atuzaginstat (COR388), in treating both diseases.

Key Points: 
  • Cortexyme also provided data demonstrating the therapeutic potential of its lead compound, atuzaginstat (COR388), in treating both diseases.
  • Previous research led by Cortexyme has demonstrated a causative association between the bacterial pathogen P. gingivalis and AD.
  • Cortexymes lead gingipain inhibitor atuzaginstat has been shown to block the neuropathology triggered by P. gingivalis in animal models.
  • Researchers have also found an association between P. gingivalis and the atherosclerotic plaques associated with cardiovascular disease, with a 2017 study by Mougeot et al.

Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease

Retrieved on: 
Wednesday, May 6, 2020
Biotechnology, Pharmaceutical, Nursing, Health, Mental health, Infectious diseases, Dental, Clinical trials, Branches of biology, Biology, Organ systems, Bacteroidetes, Bacterial vaginosis, Gynaecology, Porphyromonas gingivalis, Reproductive system, Sexual health, Neuroinflammation, Amyloid beta, Virulence factor

This latest research strengthens the connection between P. gingivalis and Alzheimers, and underscores the importance both of studying the pathogen and targeting it with potential therapeutics, such as COR388.

Key Points: 
  • This latest research strengthens the connection between P. gingivalis and Alzheimers, and underscores the importance both of studying the pathogen and targeting it with potential therapeutics, such as COR388.
  • As a Gram-negative, asaccharolytic bacterium, P. gingivalis breaks down proteins for its primary source of energy by utilizing toxic virulence factor proteases known as gingipains.
  • Cortexyme and others have also shown in animal models that P. gingivalis results in brain infection and classic AD pathology, including neurodegeneration, inflammation, beta-amyloid and tau pathology.
  • Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimers patients and tied to neurodegeneration and neuroinflammation in animal models.

Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

Retrieved on: 
Thursday, April 2, 2020
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Health, Medical specialties, Articles, RTT, Bacterial vaginosis, Bacteroidetes, Gynaecology, Porphyromonas gingivalis, Reproductive system, Periodontology, Pandemic, Parkinson's disease, the Research Presented at AAT-AD/PD, the GAIN Trial, Cortexyme, Inc.

The data is being presented this week as part of the Advances in Alzheimers and Parkinsons Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.

Key Points: 
  • The data is being presented this week as part of the Advances in Alzheimers and Parkinsons Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.
  • Over the past several years, Cortexyme and scientists around the world have been publishing evidence on the role of P. gingivalis in Alzheimers disease.
  • P. gingivalis is best known in published literature as the keystone pathogen in the development of periodontal disease.
  • The data presented today adds to the preclinical and clinical evidence supporting our approach to this devastating disease.